Reaction
Early Satiety reporting signals
As of the last recalculation, Early Satiety appears in 1,882 FAERS reports alongside 42 co-occurring drug terms. The strongest observed disproportionality signal is EXENATIDE (PRR 201.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Exenatide | 637 | 201.9 | 204.3 |
| Metformin Hcl | 189 | 41.9 | 42.0 |
| Rucaparib | 26 | 33.0 | 33.1 |
| Sucralfate Oral | 38 | 30.1 | 30.2 |
| Sucralfate Oral Suspension | 38 | 30.1 | 30.1 |
| Ruxolitinib | 147 | 24.5 | 24.6 |
| Pioglitazone | 88 | 23.6 | 23.6 |
| Sucralfate | 47 | 22.2 | 22.3 |
| Glyburide | 46 | 21.5 | 21.6 |
| Glipizide | 97 | 18.5 | 18.5 |
| Temozolomide | 28 | 14.9 | 14.9 |
| Human Insulin | 15 | 13.4 | 13.4 |
| Oral Semaglutide | 85 | 13.4 | 13.4 |
| Octreotide Acetate | 31 | 11.4 | 11.4 |
| Ezetimibe And Simvastatin | 15 | 11.0 | 11.0 |
| Glimepiride | 37 | 10.7 | 10.7 |
| Hydroxyurea | 19 | 10.0 | 10.0 |
| Regorafenib | 10 | 9.6 | 9.6 |
| Dulaglutide | 67 | 8.6 | 8.6 |
| Losartan Potassium And Hydrochlorothiazide | 8 | 7.6 | 7.7 |
| Niraparib | 14 | 7.0 | 7.0 |
| Insulin Aspart | 40 | 6.8 | 6.8 |
| Liraglutide | 30 | 6.8 | 6.8 |
| Teduglutide | 8 | 6.6 | 6.6 |
| Trifluridine And Tipiracil | 6 | 6.2 | 6.2 |
| Bosutinib | 5 | 6.2 | 6.2 |
| Capecitabine | 49 | 6.1 | 6.1 |
| Insulin Human | 21 | 5.9 | 5.9 |
| Tafamidis | 6 | 5.6 | 5.7 |
| Insulin Glargine | 115 | 5.4 | 5.4 |
| Crizotinib | 6 | 5.2 | 5.2 |
| Insulin Lispro | 59 | 4.8 | 4.8 |
| Avapritinib | 5 | 4.6 | 4.6 |
| Fam-Trastuzumab Deruxtecan-Nxki | 4 | 4.4 | 4.4 |
| Nintedanib | 12 | 4.3 | 4.3 |
| Tirzepatide | 58 | 4.1 | 4.1 |
| Droxidopa | 6 | 3.1 | 3.1 |
| Lenvatinib | 9 | 3.0 | 3.0 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 3 | 2.7 | 2.7 |
| Peginterferon Beta-1A | 3 | 2.5 | 2.5 |
| Pirfenidone | 8 | 2.2 | 2.2 |
| Relugolix | 4 | 1.9 | 1.9 |